PCT Rule 13ter — Nucleotide and/or Amino Acid Sequence Listings (MPEP Coverage Index) – BlueIron IP

PCT Rule 13ter Nucleotide and/or Amino Acid Sequence Listings

Source: Patent Cooperation Treaty (PCT)BlueIron Update:

This page consolidates MPEP guidance interpreting PCT Rule 13ter, including 69 rules from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only, it is not legal advice.

Summary

The Nucleotide and/or Amino Acid Sequence Listings is required in an international application filed under the PCT, and must be included as part of the description.

What this section covers

  • Define that this section covers the requirements for including nucleotide and amino acid sequence listings in an international application filed under the PCT.
  • Identify that the core topic is ensuring compliance with PCT Rule 5.2 for disclosing nucleotide and amino acid sequences in an international application.

Key obligations

  • State that practitioners must include a sequence listing in the description of an international application if nucleotide and/or amino acid sequences are disclosed.
  • State that Rule 13ter.1 applies to the procedure before the International Preliminary Examining Authority for sequence listings.
  • State that compliance with PCT Rule 5.2 is a key obligation for disclosing nucleotide and amino acid sequences in an international application.

Practice notes

  • Give a practical tip that practitioners should ensure the sequence listing is properly formatted and includes all required information as specified in PCT Rule 5.2.
  • Call out a common pitfall that practitioners should avoid including outdated or incorrect sequence information in the application, which could lead to rejection.

Related Provisions

Based on MPEP Last Modified: 10/30/2024 08:50:22